 Hypoglycemic Agents
"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 | | 1998 | 0 | 2 | 2 | | 1999 | 3 | 1 | 4 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 2 | 3 | | 2002 | 1 | 2 | 3 | | 2003 | 6 | 1 | 7 | | 2004 | 5 | 6 | 11 | | 2005 | 3 | 10 | 13 | | 2006 | 3 | 7 | 10 | | 2007 | 11 | 11 | 22 | | 2008 | 11 | 8 | 19 | | 2009 | 15 | 19 | 34 | | 2010 | 16 | 6 | 22 | | 2011 | 14 | 9 | 23 | | 2012 | 22 | 5 | 27 | | 2013 | 18 | 14 | 32 | | 2014 | 28 | 14 | 42 | | 2015 | 22 | 10 | 32 | | 2016 | 22 | 13 | 35 | | 2017 | 31 | 21 | 52 | | 2018 | 36 | 18 | 54 | | 2019 | 30 | 15 | 45 | | 2020 | 23 | 40 | 63 | | 2021 | 10 | 34 | 44 | | 2022 | 6 | 51 | 57 | | 2023 | 6 | 36 | 42 | | 2024 | 42 | 34 | 76 | | 2025 | 64 | 14 | 78 | | 2026 | 32 | 8 | 40 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Salive ME, Tjaden AH, Ames JR, Crandall JP, Dabelea D, Hazuda HP, Heckman-Stoddard BM, Huckfeldt PJ, Kuo S, Strotmeyer ES, Temprosa M, Venditti EM. Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA. 2026 08 18; 336(7):577-586.
-
Valdez Y, Segev N, Parimi N, Vegesna M, Brown EA, Samuels S, Van Name M, Shah AS, Wolf RM. Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis. J Pediatr Endocrinol Metab. 2026 Oct 26; 39(10):1007-1016.
-
Pistenmaa CL, Doherty L, Hermann EA, Brown AL, Dabelea D, Holguin F, Watson K, Knowler WC, Temprosa M, Barr RG. Lung function after randomization to metformin, lifestyle intervention or placebo in the Diabetes Prevention Program Outcomes Study (DPPOS). Respir Med. 2026 Oct; 262:109077.
-
DiStefano MJ, Zon J, Olson EG, Levy JF, Anderson GF, Alexander GC. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. J Manag Care Spec Pharm. 2026 Aug; 32(8):903-910.
-
Colangelo H, Nestler A, Lyon C. Not Just for Diabetes: The Next Frontier for GLP-1 Agonists. J Am Board Fam Med. 2026 Aug; 39(1).
-
van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, van Raalte DH, Muskiet MHA. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrol Dial Transplant. 2026 Jul 31; 41(8):1520-1528.
-
Martens TW, Patel BV, Wang SM, Messer LH, Pinsker JE, Malone DC, Polin MR, Brixner DI, Isaacs D, Ebekozien O. Impact of Automated Insulin Delivery on Type 2 Diabetes Measures. Am J Manag Care. 2026 Jul 01; 32(7):e222-e227.
-
Segev N, Nadeau KJ, Kelsey M, Schaaf LR, Baumgartner A, Riegler A, Wiitala K, Jenkins TM, Xanthakos SA, Helmrath MA, Inge TH, Shah AS. Glycemic Normalization Immediately Following Vertical Sleeve Gastrectomy in Adolescents With Type 2 Diabetes From the ST2OMP Study. Diabetes Obes Metab. 2026 Aug; 28(8):7555-7561.
-
Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29; 41(6):1058-1068.
-
Yu Y, Li X, Groth SW, Zaman A, Chao AM, Phelan S, Hollenbach SJ, Dreisbach C. Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure. Obstet Gynecol. 2026 Aug 01; 148(2):229-237.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|